文献速递消化与肝胆胰病理细胞病理与分子病理

Netherton综合征中蛋白水解级联失调:从分子病理到临床前药物测试

Dysregulated proteolytic cascades in Netherton syndrome: from molecular pathology to preclinical drug testing.
PubMed 文献 · J Pathol · 2026-01-09

Netherton综合征(NS)是一种罕见严重的遗传性皮肤病,由SPINK5基因功能缺失突变引起,导致LEKTI抑制剂缺陷和KLK蛋白酶过度活性,从而引发表皮过度脱屑、皮肤屏障缺陷、炎症和过敏。Spink5-/-小鼠重现人类疾病主要特征但存在新生儿致死性,双基因和三基因敲除模型已用于阐明NS相关生物学通路和验证治疗靶点。抑制LEKTI缺陷表皮中过度的KLK蛋白酶活性可逆转NS皮肤表现,其中敲除KLK5可产生显著治疗反应,但挽救最严重致死型NS还需同时抑制KLK7或TNFα。

要点

  • NS由SPINK5功能缺失突变导致LEKTI缺陷,进而引起KLK蛋白酶(KLK5、KLK6、KLK7、KLK13、KLK14)活性失调。
  • 抑制KLK5可显著改善NS皮肤表现,但挽救致死型NS需同时抑制KLK7或TNFα。
  • Spink5-/-小鼠及双/三基因敲除模型可用于NS通路研究和候选治疗药物的临床前验证。

核心结论

  • LEKTI缺陷表皮中过度KLK蛋白酶活性是NS皮肤表现的关键驱动因素,抑制该活性可逆转 cutaneous manifestations。
  • 敲除KLK5产生显著治疗反应,但挽救最严重致死型NS还需同时抑制KLK7或TNFα。
  • Spink5-/-小鼠及双/三基因敲除模型为NS病理通路研究和候选治疗药物临床前验证提供了平台。

研究设计与样本

  • 综述性文章,基于Spink5-/-小鼠及双基因和三基因敲除模型的研究证据,总结NS分子病理和临床前药物测试进展。

主要发现

  • NS由SPINK5基因功能缺失突变引起,LEKTI抑制剂缺陷导致KLK5、KLK6、KLK7、KLK13和KLK14蛋白酶调控失常。
  • Spink5-/-小鼠重现人类NS主要特征但表现新生儿致死性。
  • 双基因和三基因敲除模型已用于挽救致死性NS表型、阐明NS相关生物学通路和验证治疗靶点。
  • 抑制LEKTI缺陷表皮中过度KLK蛋白酶活性可逆转NS皮肤表现;敲除KLK5可产生显著治疗反应,但挽救最严重致死型NS还需抑制KLK7或TNFα。
  • 小鼠模型对验证体外研究或患者病例研究提出的通路和治疗靶点至关重要。

临床怎么用

  • KLK蛋白酶(尤其KLK5)及其下游通路可作为NS治疗靶点,但最严重致死型NS可能需联合抑制KLK7或TNFα。
  • Spink5-/-及双/三基因敲除小鼠模型可用于NS候选治疗药物的临床前测试和验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Netherton syndrome (NS) is a rare, severe, and often life-threatening disease for which current therapeutic approaches are limited and show variable effectiveness. NS is characterized by excessive epidermal desquamation that results in a highly defective epidermal barrier, constitutive skin inflammation, allergies, and hair abnormalities. NS develops due to loss-of-function mutations in the SPINK5 gene, which encodes the LEKTI inhibitor that regulates KLK proteases (KLK5, KLK6, KLK7, KLK13, and KLK14). These findings indicate that dysregulation of proteolytic networks underlies the extensive skin shedding and inflammation characteristic of NS. Spink5-/- mice recapitulate the major features of the human disease but exhibit neonatal lethality. Several double- and triple-knockout models have been generated to rescue the lethal NS phenotype, and have proved instrumental in studies aiming to elucidate the biological pathways involved in NS, and to identify and validate potential targets for drug development. These studies have established that inhibition of excessive KLK protease activity in LEKTI-deficient epidermis can reverse the cutaneous manifestations of NS. In particular, ablation of KLK5 results in a marked therapeutic response, although KLK7 or TNFα must also be inhibited to rescue the most severe (lethal) form of NS. Murine models have also been essential in proving or disproving putative pathways and/or therapeutic targets proposed from in vitro studies or patient case studies. Collectively, these models have provided a deeper understanding of the epidermal proteolytic cascades involved in NS pathology and in normal skin renewal. Moreover, these models offer a platform in which disease-specific candidate therapeutics can be tested and preclinically validated. © 2026 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

来源:J Pathol,查看原文。版权归原作者所有。

引用

  1. Zingkou E, Bisyris E, Pampalakis G, et al. Dysregulated proteolytic cascades in Netherton syndrome: from molecular pathology to preclinical drug testing. J Pathol. 2026. PMID: 41511866. doi:10.1002/path.70018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。